"This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment."
From the clinical trials website. Presumably this wasn't powered for efficacy - therefore, is very nice to see the dose-dependent results reach statistical signifcance as likely means a larger biological effect than oringinally thought. Anyone have the trial design specifics with stats in it?????
- Forums
- ASX - By Stock
- NEU
- Ann: Trofinetide successful in Phase 2 trial in Fragile X
Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-24
-
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B |
Open | High | Low | Value | Volume |
$13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1588 | $13.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.06 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1588 | 13.010 |
2 | 1422 | 13.000 |
2 | 3500 | 12.980 |
4 | 4561 | 12.960 |
5 | 5049 | 12.950 |
Price($) | Vol. | No. |
---|---|---|
13.060 | 1000 | 1 |
13.070 | 1709 | 2 |
13.080 | 2082 | 1 |
13.100 | 2082 | 1 |
13.120 | 2082 | 1 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online